Viewing stories from September, 2018
Small Caps publication covers DEP® irinotecan candidate’s positive performance in pancreatic cancer model
|
Small Caps, a specialist investment publication, covered the positive news that Starpharma’s DEP® irinotecan showed complete tumour regression and 100% survival in a human pancreatic cancer model. |
Read the full article here.
DEP® irinotecan outperforms in pancreatic cancer model
Melbourne, Australia: Starpharma today announced that its proprietary DEP® irinotecan development candidate showed significant efficacy and safety benefits over standard irinotecan in combination with 5-FU in a mouse xenograft model of human pancreatic cancer (Figure 1 and 2). The human pancreatic tumour model used in this study virtually did not respond to the traditional irinotecan regimen (irinotecan + 5-FU), whereas complete tumour regression and 100% survival was achieved using Starpharma’s DEP® irinotecan.